LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Device-Aided Therapies in Parkinson's disease
- 1st Edition, Volume 7 - October 1, 2024
- Editors: Per Odin, Ray Chaudhuri, Cristian Falup-Pecurariu
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 3 1 4 6 8 - 1
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 1 4 6 9 - 8
Device-Aided Therapies in Parkinson's Disease discusses the latest options from a global set of key opinion leaders and emerging specialists using a gender balanced modern and nu… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDevice-Aided Therapies in Parkinson's Disease discusses the latest options from a global set of key opinion leaders and emerging specialists using a gender balanced modern and nuanced approach. Sample chapters cover The concept of continuous dopaminergic stimulation, Apomorphine Infusion, LCIG, LECIG, Foslevodopa/Foscarbidopa, ND0612, STN-DBS, Pallidal DBS, MRgFUS, Vestibular Neurostimulation, Patient selection and choice of therapy, The future: Stem cells? Gene therapy?, The future: Trophic factors, and Devices and the dashboard for PD.
- Provides the latest information on subcutaneous device based therapies
- Includes coverage on jejunal device based therapies
- Presents information on additional surgical device based therapies
All in movement disorders
- Device-Aided Therapies in Parkinson's disease
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One Continuous dopaminergic stimulation and the transition to using continuous drug delivery in Parkinson's disease—An introduction
- Abstract
- Keywords
- 1 Introduction
- 2 Background
- 3 Is CDS as straight forward as we think?
- 4 Moving to continuous drug delivery
- 4.1 Continuous drug delivery—The future
- References
- Chapter Two Apomorphine infusion in Parkinson's disease: An update
- Abstract
- Keywords
- 1 Introduction
- 2 Background and development
- 3 Recent trial data
- 4 Key motor effects
- 5 Key non-motor effects
- 6 Quality of life data
- 7 Side effects and safety
- 8 Conclusions and future perspectives
- References
- Chapter Three Levodopa-carbidopa intestinal gel infusion in Parkinson's disease
- Abstract
- Keywords
- 1 Introduction
- 1.1 Background and development
- 1.2 Patient selection for levodopa infusion
- 1.3 The technical side of the treatment
- 1.4 Practical aspects of LCIG therapy
- 1.5 Profile of plasma levodopa concentration over time
- 2 Clinical outcomes of levodopa infusion
- 3 Clinical outcome: Key motor effects
- 3.1 Effect on motor symptoms
- 3.2 Effect on dyskinesia
- 3.3 Effect on tremor
- 3.4 Effect on freezing of gait
- 4 Clinical outcome: Key non-motor effects
- 4.1 Effect on non-motor symptoms
- 5 Clinical outcome: Quality of life data
- 5.1 Effect on quality of life
- 6 Side effects and safety
- 6.1 Surgery
- 6.2 Pump and tubing
- 6.3 Pharmacological side effects and polyneuropathy
- 6.4 Continuous drug delivery and impulse control disorders
- 7 Miscellaneous
- 7.1 Discontinuation of LCIG pump therapy
- 7.2 Cost of advanced treatments
- 8 Conclusion
- References
- Chapter Four Levodopa-entacapone-carbidopa intestinal gel infusion in Parkinson's disease
- Abstract
- Keywords
- 1 Introduction
- 2 Background and development
- 3 Trial data
- 4 Key motor effects
- 5 Key non motor effects
- 6 Quality of life data
- 7 Side effects and safety
- 8 Conclusions
- References
- Chapter Five Subcutaneous foslevodopa/foscarbidopa: A novel 24 h delivery option for levodopa
- Abstract
- Keywords
- 1 Introduction
- 1.1 The need for non oral levodopa based therapies
- 2 Subcutaneous foslevodopa and foscarbidopa
- 3 Pharmacokinetics
- 4 Clinical trials
- 5 Foslevodopa/foscarbidopa specific effects: Early morning off related akinesia (EMO) and effect on sleep
- 6 Nocturia
- 7 Cost benefit analysis
- 8 Safety
- 9 Conclusions
- Declaration of competing interest
- References
- Further reading
- Chapter Six Subthalamic deep brain stimulation surgery for Parkinson's disease
- Abstract
- Keywords
- 1 Introduction
- 2 Key landmark articles on STN-DBS for PD
- 3 Motor effects of STN-DBS in PD
- 3.1 Tremor
- 3.2 Rigidity
- 3.3 Bradykinesia
- 3.4 Motor fluctuations and dyskinesias
- 3.5 Axial symptoms
- 3.6 Medication adjustments
- 3.7 Short-term motor effects
- 3.8 Long-term motor effects
- 3.9 Study type and critical insights
- 4 Effect of STN-DBS on non-motor symptoms
- 4.1 Cognitive functions
- 4.2 Mood and psychiatric effects
- 4.3 Sleep disorders
- 4.4 Autonomic dysfunction
- 5 Effects of STN-DBS on quality of life
- 5.1 Short-term benefits on quality of life
- 5.2 Long-term benefits on quality of life
- 6 Safety, tolerability, and limitations of STN-DBS
- 6.1 Short-term safety and tolerability
- 6.2 Long-term safety, adverse effects, and limitations
- 7 Future of STN-DBS
- 8 Conclusion
- References
- Chapter Seven Globus pallidus internus deep brain stimulation in the management of movement disorders: Current evidence and future directions
- Abstract
- Keywords
- 1 Introduction and background
- 1.1 Brief History of pallidal surgery in movement disorders
- 1.2 Embryology, neurophysiology, and age-dependent developmental plasticity of the GPi
- 1.3 Neuroimaging, surgical procedure, and current technologies in GPi-DBS
- 1.4 Multidisciplinary team approach
- 1.5 Ethical considerations
- 2 GPi DBS for Parkinson's disease
- 2.1 Clinical features and pathophysiology of Parkinson's disease
- 2.2 Indications and selection criteria for GPi-DBS in Parkinson's disease
- 2.3 Connectivity and working mechanisms of GPi-DBS in Parkinson's disease
- 2.4 Clinical trials and outcome
- 3 GPI DBS in non-PD conditions
- 3.1 Dystonia
- 3.2 Tourette's syndrome (TS)
- 3.3 Aggressive behavior and self-harm
- 4 Perspectives and conclusion
- Financial support
- Conflict of interest statement
- References
- Chapter Eight Treating Parkinson's disease and movement disorders with transcranial focused ultrasound
- Abstract
- Keywords
- 1 Introduction
- 2 Technical and medical fundamentals
- 2.1 Focused ultrasound for treating for brain diseases
- 2.2 The technical implementation of the MRgFUS technology
- 3 Clinical results of MRgFUS-treatment
- 3.1 Essential tremor and other tremors
- 3.2 Parkinson's disease
- 3.3 Other indications
- 4 Conclusions
- References
- Chapter Nine Patient selection for device aided therapies
- Abstract
- Keywords
- 1 Introduction
- 2 When to consider device-aided therapies (DAT)
- 3 Available device aided therapies (DAT)
- 3.1 Levodopa-carbidopa intestinal gel (LCIG)
- 3.2 Continuous subcutaneous apomorphine infusion (CSAI)
- 3.3 Deep brain stimulation (DBS)
- 3.4 Levodopa-entacapone-carbidopa intestinal gel (LECIG)
- 3.5 Foslevodopa/foscarbidopa subcutaneous infusion
- 4 Tools for patient selection for DAT
- 4.1 Identifying advanced PD patients—CEPA-study
- 4.2 Navigate-PD
- 4.3 The Delphi Panel Consensus
- 4.4 MANAGE-PD tool (“Making informed decisions to aid timely management of Parkinson's disease)
- 5 Patient selection for newer DAT
- 5.1 Levodopa-entacapone-carbidopa intestinal gel (LECIG)
- 5.2 Foslevodopa/Foscarbidopa Subcutaneous Infusion (PRODUODOPA)
- 6 Optimizing compliance
- 7 Conclusion
- References
- Chapter Ten The future: Stem cells? Current clinical trials using stem cells for dopaminergic cell replacement
- Abstract
- Keywords
- 1 Introduction
- 2 The concept and history of cell replacement in Parkinson's disease
- 2.1 History
- 2.2 TRANSEURO: An optimized clinical trial design to test fetal DA neurons
- 3 Stem cells for transplantation therapy
- 4 Pluripotent stem cell products for PD
- 4.1 Protocols for differentiation of DA cells from hPSCs
- 4.2 hESC-derived products for PD cell therapy
- 4.3 hiPSCs-derived products for PD cell therapy
- 4.4 hParPSC-derived products
- 5 Overview over ongoing DA cell replacement clinical trials
- 5.1 ExPDite trial
- 5.2 STEM-PD trial
- 5.3 TED-A9 study
- 5.4 Kyoto trial
- 5.5 ASPIRO trial
- 6 Outlook and opinion leader conclusion
- References
- Chapter Eleven The future neurotrophic factor therapy in Parkinson's disease
- Abstract
- Keyword
- 1 Introduction
- 2 Results of NF clinical trials
- 3 Neuroprotection in early stages of disease
- 4 Reduction of oligomeric α-synuclein toxicity
- 5 Reduction of inflammation with PDGF treatment
- 6 Nanoparticle-mediated NFTs delivery
- 7 Focused ultrasound and microbubble assisted NF delivery
- 8 Conclusions
- Summary
- References
- No. of pages: 422
- Language: English
- Edition: 1
- Volume: 7
- Published: October 1, 2024
- Imprint: Academic Press
- Hardback ISBN: 9780443314681
- eBook ISBN: 9780443314698
CF
Cristian Falup-Pecurariu
Cristian Falup-Pecurariu is Head of the Department of Neurology, County Clinic Hospital from Brasov, and is Full Professor of Neurology at the Transilvania University from Brasov, Romania. He received his medical degree from the University of Medicine and Pharmacy “Iuliu Hatieganu” from Cluj-Napoca. He hold a 1 year fellowship of the European Neurological Society in movement disorders at Hospital Clinic, University of Barcelona, Spain.
During his career Cristian Falup-Pecurariu was President of the European Association of Young Neurologists and Trainees (EAYNT), EAYNT Liasion Officer with World Federation of Neurological Society, co-representative of Europe on the International Working Group for Young Neurologists and Trainees (World Federation of Neurology). He was also Secretary of the EFNS/MDS-ES Panel on Movement Disorders, member of the Educational Committee of MDS-ES, member of the MDS Leadership Task Force and European Academy of Neurology Scientific Panel Movement Disorders, member of the Teaching Course sub-Committee of the European Academy of Neurology (EAN), currently being member of the Program Committee of EAN. Falup-Pecurariu is former Chair of the Education Committee of the MDS-ES, former member of the Executive Committee of MDS-ES, former member of the International Executive Committee of MDS. He is the initiator and Course Director of the Movement Disorders Teaching Course held in Brasov (12th editions). His research focuses on motor and non-motor aspects of Parkinson’s diseases.
Affiliations and expertise
Chair, Department of Neurology, County Emergency Clinic Hospital, Associate Professor of Neurology, Faculty of Medicine, Transilvania University, Brasov, RomaniaRead Device-Aided Therapies in Parkinson's disease on ScienceDirect